EXCLUSIVE START-UP LICENSE AGREEMENT BETWEEN GLOBAL CANCER TECHNOLOGY AND UNIVERSITY OF WASHINGTON FOR BOILING HISTOTRIPSY UW COMOTION AGREEMENT 42157AExclusive Start-Up License Agreement • October 15th, 2018 • Global Cancer Technology, Inc. • Surgical & medical instruments & apparatus • Washington
This Exclusive License Agreement (this “Agreement”), effective as of March 8, 2018 (the “Effective Date”), is made and entered into between the University of Washington, a public institution of higher education and an agency of the state of Washington, (“University”), and Global Cancer Technology, a corporation in the state of Nevada (“Company”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. AMENDMENT NO. 2 TO EXCLUSIVE START- UP LICENSE...Exclusive Start-Up License Agreement • March 1st, 2022 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 2 to the Exclusive Start-Up License Agreement (this “Amendment No. 2”) effective as of December 15, 2021 (the “Amendment No. 2 Effective Date”), is entered into between the University of Washington (“University”), and Neoleukin Therapeutics, Inc. (“Company”). “Party” or “Parties” shall mean, individually, University or Company as the context requires and, collectively, both University and Company.
Amendment NO. 5 to EXCLUSIVE START-UP LICENSE Agreement between SANA BIOTECHNOLOGY, INC. and UNIVERSITY OF WASHINGTONExclusive Start-Up License Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 5 (“Amendment No. 5”), with an effective date of as of the date of the last signature (“Amendment No. 5 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
Amendment NO. 6 to EXCLUSIVE START-UP LICENSE Agreement between SANA BIOTECHNOLOGY, INC. and UNIVERSITY OF WASHINGTONExclusive Start-Up License Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 6 (“Amendment No. 6”), with an effective date as of the date of the last signature (“Amendment No. 6 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
Amendment NO. NINE (9) to [***] EXCLUSIVE START-UP LICENSE Agreement between Sana biotechnology, Inc. and UNIVERSITY OF WASHINGTONExclusive Start-Up License Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 9 (“Amendment No. 9”), with an effective the date of last signature (“Amendment No. 9 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. EXCLUSIVE START-UP LICENSE AGREEMENT BETWEEN...Exclusive Start-Up License Agreement • August 12th, 2019 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • Washington
This Exclusive License Agreement (this “Agreement”), effective as of the date of last signature (the “Effective Date”), is made and entered into between the University of Washington, a public institution of higher education and an agency of the state of Washington, (“University”), and Neoleukin Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (“Company”).
Amendment NO. SEVEN (7) to EXCLUSIVE START-UP LICENSE Agreement between SANA BIOTECHNOLOGY, INC. and UNIVERSITY OF WASHINGTONExclusive Start-Up License Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 7 (“Amendment No. 7”), with an effective date of as of the date of the last signature (“Amendment No. 7 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
AMENDMENT NO. 4 TO EXCLUSIVE START-UP LICENSE AGREEMENT BETWEEN SANA BIOTECHNOLOGY, INC. AND UNIVERSITY OF WASHINGTONExclusive Start-Up License Agreement • January 28th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 4 (“Amendment No. 4”), with an effective date of January 21, 2021 (“Amendment No. 4 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
AMENDMENT NO. 1 TO EXCLUSIVE START-UP LICENSE AGREEMENT BETWEEN CYTOCARDIA, INC. AND UNIVERSITY OF WASHINGTONExclusive Start-Up License Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 1 (“Amendment No. 1”), with an effective date of November 6, 2019 (“Amendment No. 1 Effective Date”), is entered into by and between Cytocardia, Inc. (“Company”) and University of Washington (“University”).
AMENDMENT NO. 2 TO EXCLUSIVE START-UP LICENSE AGREEMENT BETWEEN CYTOCARDIA, INC. AND UNIVERSITY OF WASHINGTONExclusive Start-Up License Agreement • January 28th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 2 (“Amendment No. 2”), with an effective date of July 16, 2020 (“Amendment No. 2 Effective Date”), is entered into by and between Cytocardia, Inc. (“Company”) and University of Washington (“University”).
Amendment NO. 10 to EXCLUSIVE START-UP LICENSE Agreement between CYTOCARDIA, INC. and UNIVERSITY OF WASHINGTONExclusive Start-Up License Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 10 (“Amendment No. 10”), with an effective date of the date of last signature (“Amendment No. 10 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
EXCLUSIVE START-UP LICENSE AGREEMENT BETWEEN CYTOCARDIA, INC. AND UNIVERSITY OF WASHINGTON FORExclusive Start-Up License Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • Washington
This Exclusive License Agreement (“Agreement”), is dated and effective as of the date of last signature (the “Effective Date”), and is made and entered into between the University of Washington, a public institution of higher education and an agency of the state of Washington, acting through UW CoMotion, (“University”), and Cytocardia, Inc., a corporation organized under the laws of the State of Delaware (“Company”).
AMENDMENT NO. 1Exclusive Start-Up License Agreement • March 25th, 2021 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 1 to the Exclusive Start-Up License Agreement (this “Amendment No. 1”) effective as of July 24, 2020 (the “Amendment No. 1 Effective Date”), is entered into between the University of Washington (“University”), and Neoleukin Corporation, formerly known as Neoleukin Therapeutics, Inc. (“Company”).
Amendment NO. Eight (8) to EXCLUSIVE START-UP LICENSE Agreement between Sana biotechnology, Inc. and UNIVERSITY OF WASHINGTONExclusive Start-Up License Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 8 (“Amendment No. 8”), with an effective the date of last signature (“Amendment No. 8 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
Amendment NO. 11 to EXCLUSIVE START-UP LICENSE Agreement between CYTOCARDIA, INC. and UNIVERSITY OF WASHINGTONExclusive Start-Up License Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 11 (“Amendment No. 11”), with an effective date of the date of last signature (“Amendment No. 11 Effective Date”), is entered into by and between Sana Biotechnology, Inc. (“Company”) and University of Washington (“University”).
